Mesa Laboratories Inc: Form 10-Q for the period ended Dec 31, 2019
Filed with the SEC on Feb 10, 2020 and accepted by EDGAR at Feb 10, 2020, 08:01 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2019-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2019-10-01 to 2019-12-31 | $31.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 9 months2019-04-01 to 2019-12-31 | $83.5m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2019-10-01 to 2019-12-31 | $17.0m | us-gaap:CostOfRevenue |
| Cost of revenue | 9 months2019-04-01 to 2019-12-31 | $37.2m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2019-10-01 to 2019-12-31 | $14.7m | us-gaap:GrossProfit |
| Gross profit | 9 months2019-04-01 to 2019-12-31 | $46.3m | us-gaap:GrossProfit |
| Research and development | 3 months2019-10-01 to 2019-12-31 | $2.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2019-04-01 to 2019-12-31 | $4.0m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2019-10-01 to 2019-12-31 | −$3.4m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2019-04-01 to 2019-12-31 | $6.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2019-10-01 to 2019-12-31 | $1.9m | us-gaap:InterestExpense |
| Interest expense | 9 months2019-04-01 to 2019-12-31 | $3.5m | us-gaap:InterestExpense |
| Income tax | 3 months2019-10-01 to 2019-12-31 | −$573.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2019-04-01 to 2019-12-31 | $792.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2019-10-01 to 2019-12-31 | −$4.6m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 9 months2019-04-01 to 2019-12-31 | $3.0m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2019-10-01 to 2019-12-31 | −$1.06 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2019-04-01 to 2019-12-31 | $0.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2019-10-01 to 2019-12-31 | −$1.06 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2019-04-01 to 2019-12-31 | $0.73 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2019-10-01 to 2019-12-31 | 4,367,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2019-04-01 to 2019-12-31 | 4,418,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2019-04-01 to 2019-12-31 | $18.2m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2019-04-01 to 2019-12-31 | $935.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2019-04-01 to 2019-12-31 | $2.0m | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2019-12-31 | $74.0m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2019-12-31 | $120.7m | us-gaap:AssetsCurrent |
| Total assets | At period end2019-12-31 | $423.5m | us-gaap:Assets |
| Current liabilities | At period end2019-12-31 | $25.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2019-12-31 | $189.3m | us-gaap:Liabilities |
| Shareholders' equity | At period end2019-12-31 | $234.2m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001437749-20-002116. Last ingested by Listed: Nov 13, 2026, 07:45 ET. Listed shows no prices and gives no investment advice.